AI has become a fixture of biopharma strategy conversations. But the gap between confidence and actual impact is wider than most commercial teams realize.
Evaluate recently partnered with BioPharma Dive to survey 150 senior biopharma executives on their companies’ current and future plans to integrate AI into commercial processes. What they found was a market at a crossroads: broad enthusiasm, uneven results, and a tool problem that most organizations haven’t fully reckoned with yet.
The data points to four specific risks facing commercial teams right now from the quality of the data AI is being trained on, to the defensibility of its outputs, to the competitive advantage being built by the minority of teams already using purpose-built pharma AI.
For pharma companies and investors tracking the commercial side of the market, this is the clearest picture yet of where AI adoption stands and what separates the teams getting real value from those still experimenting.
